Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough Ecg Trial

Next Previous
Trial Profile

A Double-Blind Randomized Crossover Trial to Define the Ecg Effects of Droxidopa Using a Clinical and a Supratherapeutic Dose Compared With Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: a Thorough Ecg Trial

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Droxidopa (Primary) ; Moxifloxacin
  • Indications Attention-deficit hyperactivity disorder; Bacterial infections; Fibromyalgia; Orthostatic hypotension; Parkinson's disease
  • Focus Adverse reactions

Most Recent Events

  • 19 May 2015 Pooled analysis (102,301,306) cardiac repolarization results presented at the 30th Annual Scientific Meeting of the American Society of Hypertension.
  • 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 20 Jun 2011 Results have been reported in a Chelsea Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top